Centene (CNC) Earnings Date & Reports

Centene delivered robust First Quarter 2026 results, with premium and service revenues of $44.7 billion, a 5% increase from $42.5 billion in the prior year. Medicaid contributed $23.6 billion (up 6%), Medicare $10.3 billion (up 18%), while commercial fell to $9.6 billion (down 6%). Total revenues hit $49.9 billion, exceeding Wall Street's $47.6 billion consensus.

GAAP net earnings rose to $1.541 billion, or $3.11 diluted EPS, from $1.311 billion, or $2.63 EPS, last year. Adjusted diluted EPS climbed 16% to $3.37, significantly topping expectations. The HBR improved 20 basis points to 87.3%, aided by Medicaid (93.1%) and Medicare (84.9%) efficiencies, though commercial rose slightly to 75.3%. SG&A ratio fell 30 basis points to 7.6%. Total at-risk membership dipped to 26.3 million from 27.9 million, reflecting commercial and Marketplace reductions offset by Medicare growth.

Guidance updates included premium revenues raised to $171.0-$175.0 billion and adjusted EPS floor to >$3.40. The company also reduced debt by $1.0 billion.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your stock analysis workflow.

Market Reaction and Investor Sentiment

Centene's shares jumped more than 14% in the session following the April 28 release, outperforming the broader healthcare sector amid enthusiasm for the earnings beat and guidance hike. Investors interpreted the results as validation of margin expansion and cost discipline, though some noted membership declines in commercial lines as a watch item. Sentiment turned positive, with analysts highlighting the raised outlook as a key driver for confidence in 2026 execution.

Forward Outlook and Key Factors to Monitor

Centene's elevated full-year 2026 guidance signals optimism, with adjusted diluted EPS now targeted above $3.40 and premium revenues at $171.0-$175.0 billion. This reflects anticipated Medicaid stability post-redeterminations and Medicare Prescription Drug Plan (PDP) strength, alongside cost leverage.

Investors should track HBR trends across segments, as Medicare Advantage bids and utilization patterns could pressure margins. Continued SG&A efficiencies and debt reduction efforts will support cash flow. Marketplace dynamics, including enrollment for open enrollment later in 2026, remain critical amid commercial softness.

Broader factors include state Medicaid funding, regulatory changes in healthcare, and economic influences on demand. Upcoming catalysts encompass Q2 results in July and progress toward long-term earnings growth. Monitoring these will provide insights into sustained recovery.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations